TSC2 and neoplasm: A multicenter, histology-agnostic, single-arm prospective phase II trial of the mTORC1 inhibitor, Everolimus, in patients with solid tumors mainly harboring TSC1/TSC2 mutations ultimately failed, showing no association between these genomic alterations and response to targeted treatment in a broad spectrum of neoplasms, not including RCCs [33].